Generic Medicine Info
Should be taken with food.
Uncontrolled HTN; history of pulmonary, pericardial, and retroperitoneal fibrotic disorders; cardiac valvular disorders. Toxaemia of pregnancy, history of puerperal psychosis. Concomitant use w/ dopamine antagonists.
Special Precautions
Patients w/ severe CV disease, Raynaud's syndrome, peptic ulcer, GI bleeding. Renal or hepatic impairment. Pregnancy and lactation. Patient Counselling May impair ability to drive or operate machinery. Monitoring Parameters Monitor BP; serum prolactin level (mthly until normalised); echocardiogram (at baseline and 6-12 mthly); ESR, chest X-ray, and serum creatinine level; signs and symptoms of pleuropulmonary disease, ureteral/abdominal vascular obstruction. Perform pregnancy test prior to initiation of therapy.
Adverse Reactions
Abdominal pain, angina, breast pain, confusion, constipation, depression, dyspepsia, epigastric pain, gastritis, hallucinations, headache, nausea, syncope, postural hypotension, somnolence, allergic skin reactions, alopecia, cardiac valvulopathy, constrictive pericarditis, drowsiness, dyskinesia, erythromelalgia, hypersexuality, hypotension, increased libido, leg cramps, pericardial effusion, pathological gambling, peripheral oedema, pleural effusion/fibrosis, pleuritis, pulmonary/retroperitoneal fibrosis. Rarely, digital vasospasm, epistaxis, hot flushes, muscle weakness, palpitation, paraesthesia, transient hemianopia, vomiting.
Drug Interactions
Increased risk of orthostatic hypotension when used w/ antihypertensives. Additive therapeutic effect w/ levodopa. Increased systemic bioavailability w/ macrolide antibiotics (e.g. erythromycin).
CIMS Class
Antiparkinsonian Drugs / Other Drugs Affecting Hormonal Regulation
ATC Classification
G02CB03 - cabergoline ; Belongs to the class of prolactine inhibitors. Used to suppress lactation.
N04BC06 - cabergoline ; Belongs to the class of dopamine agonist. Used in the management of Parkinson's disease.
Disclaimer: This information is independently developed by CIMS based on cabergoline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in